The issue of immediate provision of availability of medicines for the treatment of coronavirus infection is under special control of the Government of RK.
As part of the fight against coronavirus infection, the Single distributor is taking measures to provide medical organizations of the country with medicines.
Since last year, medicines have been shipped to the medical organizations of the country continuously according to the schedule according to the protocol of treatment of CVI for 91 names of medicines.
It is worth noting that the Single distributor makes purchases in the volume formed by medical organizations and delivers in accordance with the delivery schedule of concluded contracts with medical organizations.
Provision of the drug "Tocilizumab" (Actemra)
The Single distributor provides the drug "Tocilizumab" under the trade name "Actemra" in three dosage forms and dosages as part of the provision of GVFMC and CSHI at the inpatient level for 2021.
The delivery of the drug to medical organizations is provided in time according to the schedule.
The delivery of the drug to medical organizations is provided in a timely manner according to the schedule. The purchase of an additional volume of medicines is carried out on the basis of applications from medical organizations of the country to the Single distributor.
The Single distributor, taking into account the additional volume declared by medical organizations, purchased the drug Tocilizumab (Actemra) in the amount of 7043 vials for 2021 (taking into account the additional volume, an increase of 2 times compared to the application at the beginning of the year).
As of August 3, 2021, the Single distributor delivered 4,517 vials to medical organizations of the republic. At the same time, 771 vials were shipped ahead of schedule.
On August 2, 2021, the Supplier delivered the drug in the amount of 1113 vials ahead of schedule to the warehouses of the Single Distributor.
Due to the epidemiological situation, in order to meet the additional needs of medical organizations, the Single distributor has worked out the issue of additional delivery of "Aktemra" in the amount of 1277 vials in two dosages.
The demand for this drug has increased worldwide due to the increase in the morbidity of COVID-19. To ensure additional applications for the drug from medical organizations, the Single distributor is working on the issue of purchasing an additional volume of the drug "Tocilizumab" within the framework of direct contracts and other mechanisms for the supply of the drug.
Provision of the drug "Remdisivir"
The drug Remdesivir, lyophilized powder 100 mg, is not included in the List of SD for 2021, approved by the order of MHRK dated July 28, 2020 No. KR DSM-90/2020.
At the same time, the Single distributor purchased the drug "Remdesivir, powder for making a solution for intravenous injection of 100 mg" for 2020 on behalf of MHRK in accordance with Chapter 19 of the Rules, as well as a non-reduced stock on the basis of the letter of MHRK dated August 12, 2020 No. 12-1-12/5011-I.
The drug Remdesivir, lyophilized powder 100 mg, was included in the Clinical Protocol for the Diagnosis and treatment of coronavirus infections COVID-19 in adults as part of participation in a clinical trial on April 1, 2021.
According to the data of the Regional Healthcare and public healthcare Departments of Nur-Sultan, Almaty, Shymkent, the drug Remdesivir was purchased by medical organizations independently and is available in sufficient quantities.
In addition, on the basis of the order of the Ministry of Healthcare of the Republic of Kazakhstan, on July 30, 2021, the Single distributor purchased an additional 124,707 vials of the drug Remdesivir with a delivery schedule until August 15, 2021.
It should be noted that the drugs "Tocilizumab" and "Remdesivir" are included in the Clinical Protocol for the diagnosis and treatment of coronavirus infection COVID-19 in adults, as experimental medicines.
That is, it is prescribed to the patient only when the informed consent is signed personally or by his legal representative. Drugs are prescribed on the basis of a decision of a medical council, when the potential benefit of the drug exceeds the potential risk to the patient.
At the same time, the drugs "Tocilizumab" and "Remdesivir" are not included in the formed 2-month non-reduced stock of drugs for the treatment of COVID-19.
The Single distributor constantly monitors the availability of medicines and medical products in the warehouses of the Single distributor, and the balance in medical organizations.
The purchase of an additional volume of medicines is carried out based on the analysis of consumption by medical organizations and monitoring of balance in the warehouses of SK-Pharmacy and in medical organizations of the country. On a weekly basis, information is provided to the Ministry of Healthcare of RK.
At the same time, drawing conclusions from the first wave of the pandemic, in order to quickly and effectively solve the issue of saturating hospitals and dispensary centers with all the necessary medicines and medical products for the treatment of coronavirus infection, operational measures were developed to stabilize the situation associated with the CVI.
As part of the fight against coronavirus infection, the Single distributor has taken measures to provide medical organizations of the country with medicines. For this purpose, stocks of medicines have been created in medical organizations, as well as in the warehouses of the Single distributor for prompt shipment, depending on the epidemiological situation.
First: a 2-month stock of drugs is provided in the warehouses of the SD
The Ministry of Healthcare has approved 38 items of medicines of non-reduced stock for the treatment of COVID-19 in the amount of 6.4 billion tng. The volume of these positions will allow to cover 60 thousand patients per month with treatment. The volume of a two-month stock of medicines for COVID-19 is distributed and stored at the HUBs of the Single distributor upon the consumption of medicines by regions in 2020: Almaty – 35%; Nur-Sultan - 30%; Aktobe - 15%; Shymkent - 20%.
Medicines of a non-reduced stock are used by the Single distributor at the request of medical organizations in the event of a sharp increase in morbidity and a shortage in drugs for the treatment of COVID-19. As it is shipped to medical organizations, the used volume of the non-reduced stock is promptly purchased and updated. The volume of the non-reduced stock is purchased by the Single distributor out of the requests of medical organizations.
Second: the stock of drugs in medical organizations is provided
Since last year, medicines have been shipped to the country's medical organizations continuously according to the schedule according to the protocol of treatment of CVI, this is 91 positions. It was shipped to medical organizations in the amount of 13.8 billion tenge.
Third: the list of odp has been expanded by 5 names (antipyretic drugs Paracetamol and Ibuprofen, anticoagulants Rivaroxaban, Apixaban and Dabigatran). During the period of 2021, these drugs were shipped to the polyclinics of the republic in the amount of 2 billion tenge. At the same time, 1 billion tng of them were released to the population according to prescriptions.
Fourth: the purchase of drugs for the retail network has been carried out
According to the requests of akimats, a 2-month stock of 26 items was formed in the amount of 1.8 billion tenge for intervention in the retail network, in case of a shortage. Also, we purchased 10 million masks (including 500 thousand children's masks for the amount of 0.4 billion tenge). Masks are also intended for sale through retail pharmacies in case of acute need in the regions. This stock is stored on 4 hubs of the Single distributor. The stocks are used at the request of the regions, and if necessary, they are urgently shipped.
Fifth: a stock of PPE-s has been formed
In the amount of 200 thousand disposable suits, which are stored at the HUBs of the Single distributor. The need for PPE in each region depends on the outbreak of the disease, and therefore stocks have been created at 4 Hubs of the Single distributor for prompt delivery.
Sixth: the formation of a stock of medical gloves
A stock of disposable medical gloves has been formed within the framework of the signed memorandum with "Chevron" company for the provision of humanitarian aid in the amount of 10 million pairs at 4 hubs of the Single distributor.
Seventh: stocks of syringes for vaccination of the population have been formed
When the voluntary vaccination of the population against coronavirus infection begins, the necessary stock of disposable self-destructing syringes is being formed.
Thus, 22.7 million syringes were purchased to cover the population with vaccination, taking into account the introduction of the I and II components of the vaccine.12.82 million units of the purchased syringes were delivered to the warehouses of the Single Distributor according to the schedule, of which 10.9 million units were shipped to the regions on the basis of the orders of the healthcare departments, which is enough for the shipped volume of the CVI vaccine.
For reference:
The purchase of medicines and medical products through the Single distributor is regulated by the Rules for organizing and conducting the purchase of medicines and medical products, pharmaceutical services, approved by Government Decree №375.
The list of medicines included in the protocol of diagnosis and treatment of CVI is approved by the Ministry of Healthcare of RK. The Joint Commission on the Quality of Medical Services (JCQ) of MHRK develops recommendations for improving clinical protocols and medical provision. On the basis of clinical protocols, the Formulary Commission of MHRK includes medicines in the orders and the list of the Single distributor for purchase. The protocol developers are leading infectious diseases specialists, pulmonologists and other clinical specialists of RK.
 (14) (1).png)
.png)
 (9).png)
.jpeg)